Jennifer Riley's most recent trade in Avalo Therapeutics Inc was a trade of 95,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Jennifer Riley | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Jennifer Riley | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 637 | 2,655 | - | 4.1 | 2,612 | Common Stock |
| Avalo Therapeutics Inc | Jennifer Riley | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |